NCT05749588 2026-04-16
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Phase 2 Recruiting
Clinical Trials
15 trialsNCT07062965 2026-04-16
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Phase 3 Recruiting
NCT07340541 2026-04-13
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT06428396 2026-03-24
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT07024173 2026-01-26
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Recruiting
NCT07002177 2026-01-07
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05508906 2025-10-22
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1 Recruiting
NCT06680921 2025-09-22
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05949541 2024-02-08
BCTOP-L-M01
Fudan University
Phase 2 Recruiting
NCT05954442 2024-01-16
BCTOP-T-M03
Fudan University
Phase 3 Recruiting
NCT05983107 2023-08-09
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting